RxDoctor Payments Data

Joel George, MD

Ophthalmology · Weslaco, TXNPI 1689718819

Payments from drug & device makers

$2,222in general payments, 2019–2025

Across 71 payments — averaging $31.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$427
  • Novartis$395
  • Alcon$286
  • Genentech USA, Inc.$260
  • Regeneron Healthcare Solutions, Inc.$239
  • Bausch & Lomb Americas Inc.$150
  • plus $465 from 10 others

What the payments were for

  • Food & beverage$2,17798%
  • Gifts$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,222 in reported general payments places this provider in the 50th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$986,286
Medicare patients
622
Services billed
9,807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium189$75,779
LumiganBimatoprost159$75,703
CombiganBrimonidine Tartrate/Timolol199$67,457
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol323$61,399
RestasisCyclosporine34$47,221
Bromfenac Sodium289$45,365
SimbrinzaBrinzolamide/Brimonidine Tart151$29,858
Cyclosporine35$27,888
XiidraLifitegrast16$22,642
Prednisolone Acetate392$17,184
IlevroNepafenac34$14,301
Ketorolac Tromethamine448$13,104
Travoprost84$12,835
Latanoprost798$11,750
Brinzolamide61$11,446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Restasis Multidose, Alphagan P$427$205,321421 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Besivance$128$83,052216 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$150$29,95231 claims
AlconSimbrinza$286$29,858151 claims
NovartisIlevro$395$14,30134 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$32$12,15931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Weslaco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →